<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01858909</url>
  </required_header>
  <id_info>
    <org_study_id>TRA-172</org_study_id>
    <nct_id>NCT01858909</nct_id>
  </id_info>
  <brief_title>Efficacy of Melatonin in Patients With Severe Sepsis or Septic Shock</brief_title>
  <official_title>Phase III, Prospective, Randomized, Double-blind Clinical Trial to Evaluate the Efficacy of Melatonin in Patients With Severe Sepsis or Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aragon Institute of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministerio de Sanidad, Servicios Sociales e Igualdad</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aragon Institute of Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES. To establish the therapeutic efficiency of melatonin in adult patients with
      severe sepsis and septic shock.

      Specifically:

        1. To evaluate the survival to 28 days of mechanical assisted ventilation, days with
           vasoactive drugs, need of hemodialysis-hemofiltration, superinfection and evolution
           towards the failure of other organs.

        2. To evaluate, waiting for reduction under the influence of the treatment with melatonin,
           :

             1. clinical - analytical parameters of sepsis;

             2. levels of cytokines;

             3. oxidative and nitrosative stress;

             4. acute-phase proteins (APP), specially of the ITIH4;

             5. immune response;

             6. endocrine response.

      METHODOLOGY. Patients will be randomized in two groups, n = 55 in each group: 1) treatment
      with melatonin 30mg/12 hours 28 days; 2) placebo.

      Determinations: a) clinical - analytical parameters relative to the sepsis; b) melatonin
      plasmatic levels; c) quantification of malonyldialdehyde and 4-hydroxynonenal, protein
      carbonyl content, nitrites, erythrocyte membrane fluidity, and superoxide dismutase,
      catalase, glutathione reductase and glutathione peroxidase activity; d) Interleukins-1,2,4,5,
      6, 7,8,10,12,13, IFN-γ; TNF-α and GM-CSF; e) acute-phase proteins: PCR, haptoglobin, Apo A-I,
      α1-GPA and ITIH4; f) lymphocytes T, B, NK, T CD4, and T CD8, and immunoglobulins; g)
      cortisol, aldosterone, ACTH, ADH, insulin, glucagon and 25-hydroxyvitamin D3. Data will be
      analyzed following a prospectively define plan and by intention-to-treat (ITT) analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be done in the Hospital Clinico Lozano Blesa (Zaragoza, Spain), promoted by
      the Health Science Aragon Institute and its principal investigator is F. Agustín García Gil
      (Surgical Service). It will start in April-May 2013 and will finish 12 months later
      approximately. The study sponsor is I+CS (Aragon Institute of Health Sciences).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 month</time_frame>
    <description>Mortality at 28 days of study entry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical evolution parameters</measure>
    <time_frame>1 month</time_frame>
    <description>Days of mechanical ventilation. Days with vasoactive drugs. Days with hemodialysis or hemofiltration. Superinfection of organs other than the initial cause of the sepsis. Progression to other organs fail after starting the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical evolution</measure>
    <time_frame>1 month</time_frame>
    <description>clinical - analytical parameters relative to the sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative-nitrosative parameters</measure>
    <time_frame>1 month</time_frame>
    <description>Melatonin plasmatic levels Quantification of malonyldialdehyde and 4-hydroxynonenal Protein carbonyl content Nitrites Erythrocyte membrane fluidity Superoxide dismutase, catalase, glutathione reductase and glutathione peroxidase activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory parameters</measure>
    <time_frame>1 month</time_frame>
    <description>Interleukins-1,2,4,5, 6, 7,8,10,12,13, IFN-γ; TNF-α and GM-CSF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute phase proteins</measure>
    <time_frame>1 month</time_frame>
    <description>PCR, haptoglobin, Apo A-I, α1-GPA and ITIH4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune parameters</measure>
    <time_frame>1 month</time_frame>
    <description>Lymphocytes T, B, NK, T CD4, and T CD8, and immunoglobulins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endocrine parameters</measure>
    <time_frame>1 month</time_frame>
    <description>Cortisol, aldosterone, ACTH, ADH, insulin, glucagon and 25-hydroxyvitamin D3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Severe Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline every 12 hours for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral 30mg/12hours melatonin 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>Administration via oral or via a nasogastric tube followed by 20mL saline</description>
    <arm_group_label>Melatonin</arm_group_label>
    <other_name>Liquid 1 mg/mL Melatonin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients (males and females) over 18 years who meet the diagnostic criteria for severe
             sepsis or septic shock secondary to community-acquired pneumonia or hospital and or
             intra-abdominal infection

        Exclusion Criteria:

          -  Patient with more than 24 hours from the first documentation of organ dysfunction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco A García-Gil, Physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario Lozano Blesa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2013</study_first_submitted>
  <study_first_submitted_qc>May 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2013</study_first_posted>
  <last_update_submitted>May 17, 2013</last_update_submitted>
  <last_update_submitted_qc>May 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

